Liquid Biopsies – Products

Bluestar Genomics are to share their new non-invasive data for earlier cancer detection at the 11th CNAPs International Symposium.

Objectives are to characterize and quantify Stroma Liquid Biopsy™ biomarkers so as to correlate to the Tumor-Stroma Ratio scoring methods developed by Leiden University.

Download this application note for advice on optimizing your NGS workflow, the benefits this brings to cancer research and how established methods can obtain more information more quickly.

Start Codon, located in the heart of the Cambridge Cluster, aims to provide a much-needed world-class life science accelerator that offers significant funding and support to rapidly translate the most disruptive and innovative research into successful start-up companies.

Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery.

This test quantifies BCR-ABL the gene fusion that causes CML, in the blood. Though no criteria been established to determine when therapy can be stopped, the detection of low BCR-ABL levels may help physicians provide their patients with the best possible treatment.

First-of-its-kind technology advances the ability to detect and analyze exosomes with high sensitivity and specificity.

Biotech Support Group is proud to announce their role in the recent book, seeking to fill the technology gap for the study of proteins function at a proteome scale.